查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830993

经由黏膜给药系统市场

Transmucosal Drug Delivery Systems Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

经黏膜给药系统市场规模预计将从2024年的820.2亿美元成长到2031年的1,294.6亿美元，2025年至2031年期间的复合年增长率为6.2%。分析师观点：经黏膜给药利用黏膜（包括口腔、鼻腔、直肠、阴道、眼部及肺部黏膜）进行给药。与传统给药途径相比，此方法具有显着优势，例如生物利用度更高、起效更快、避免首过代谢以及给药便捷。本报告根据经黏膜给药系统市场的当前趋势及其在预测期内的预期影响，重点介绍了成长机会。

推动经黏膜给药系统成长的因素

经黏膜给药因其持续的疗效而备受青睐。鼻腔内、颊部、舌下和直肠给药等非侵入性给药方式无需专业人员即可进行全身给药，这对护理人员和患者尤其有益。此外，这些方法迅速且首过代谢降低，使其成为安宁疗护和临终关怀的理想选择，能够快速缓解症状。因此，经粘膜给药系统越来越多地用于治疗心血管疾病、糖尿病和慢性呼吸系统疾病等慢性疾病。 PubMed Central 于 2020 年 1 月发表的一项研究，评估了二氢麦角胺 (DHE) 在健康受试者中的安全性和药物动力学，研究内容包括经鼻 DHE 粉剂 (STS101)、经鼻 DHE 喷雾剂 (Migranal) 和肌肉注射 (IM) DHE。研究结果表明，STS101 是一种用户友好的非注射偏头痛急性治疗方法，具有良好的耐受性，有望提供快速、持续的疼痛缓解，同时抑制偏头痛症状且不復发。

许多药物都有口腔黏膜剂型，包括心血管药物、镇静剂和止痛剂。可生物降解的口腔膜有助于药物传递到体循环，这对吞嚥困难、频繁呕吐、高血压、心臟病发作、气喘、噁心、瘫痪和精神健康障碍患者尤其有利。这些速溶口腔膜是贴在舌头或其他口腔黏膜组织上的薄黏性条带。

因此，易于管理、生物利用度高、全身药物可用性和快速作用的优势正在推动经黏膜给药系统市场的成长。

战略洞察

报告细分和范围

《2031年全球经黏膜给药系统市场分析》是一项针对製药业的综合性研究，重点在于分析全球市场趋势。该报告旨在提供市场概览，并根据系统、最终用户和地理进行详细细分。报告包含主要市场参与者的关键统计数据，并重点介绍了市场中的重要趋势和机会。全球经黏膜给药系统市场报告涵盖北美（美国、加拿大和墨西哥）、欧洲（德国、法国、义大利、英国、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、澳洲、韩国和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地区）。

以系统为基础的洞察市场分为鼻肺给药系统、颊黏膜及舌下给药系统、阴道给药系统及其他系统。 2023年，鼻肺给药系统占据了经黏膜给药系统市场的最大份额，预计在2023年至2031年期间将呈现最高的复合年增长率。

基于最终用户的洞察市场根据最终用户分为医疗机构、家庭护理机构和其他类型。医疗机构在2023年占据了最大的市场份额，这要归功于医院拥有一流的设施和经验丰富的医疗专业人员。此外，预计家庭护理机构在2023年至2031年期间的复合年增长率最高。

区域分析：从地理上看，市场细分为北美、亚太、欧洲、中东和非洲以及南美和中美。 2023年，北美占据了经黏膜给药系统市场的最大份额，其中美国占据主导地位。这种主导地位的形成源于糖尿病、气喘和心血管疾病等慢性疾病的发病率不断上升，以及主要产业参与者推出的产品数量不断增加。

经黏膜给药系统市场报告范围：产业发展与未来机会：经黏膜给药系统市场的预测可以帮助利害关係人规划其成长策略。根据公司新闻稿，全球市场领导企业的几项策略发展概述如下：

2024年2月，Aquestive Therapeutics, Inc. 在华盛顿特区举行的美国过敏、气喘和免疫学会 (AAAAI) 2024 年年会上展示了一张海报，展示了两项已完成的舌下 Anaphylm（肾上腺素）膜临床研究的阳性药物动力学 (PK) 和药效学 (PD)资料。 2022年8月，iX Biopharma Ltd 启动了 IXB-322，这是一项扩展其产品线的新计划，专注于开髮用于治疗痴呆症和其他疾病中的躁动的舌下右美托咪啶薄片。此项努力是 iX Biopharma 利用其专有的 WaferiX 药物传输平台技术重新利用现有核准药物的策略的一部分。 2021 年 5 月，日本 Zeria 集团旗下的 Tillotts Pharma AG 推出了 AsacolTM 1g（美沙拉嗪），为其胃肠病学产品组合增添了一种新药，这是一种用于治疗成人轻度至中度溃疡性直肠炎症状的高强度栓剂。此次发布旨在为胃肠道疾病患者提供创新疗法，提供一种每日只需服用一次的便捷治疗选择。 2021年4月，梯瓦製药工业有限公司的美国分公司梯瓦製药美国公司宣布在美国推出Casana 1（美沙拉嗪）栓剂的仿製药，用于治疗活动性溃疡性直肠炎（溃疡性直肠结肠炎）。经黏膜给药系统市场报告中介绍的主要公司包括梯瓦製药工业有限公司、信诺集团、BioDelivery Sciences International, Inc、3M、汉高芬兰公司、葛兰素史克公司、Aquestive Therapeutics, Inc、Camurus AB、Ximedica和Noven Pharmaceuticals, Inc.。这些领导企业专注于扩大和多样化其市场占有率和客户群，抓住市场商机。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：经黏膜给药系统市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：经黏膜给药系统市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：经黏膜给药系统市场－全球市场分析

  • 经黏膜给药系统－全球市场概览
  • 经黏膜给药系统－全球市场及2031年预测

第七章：经黏膜给药系统市场-收入分析-按系统，2021-2031

  • 概述
  • 鼻肺
  • 颊部和舌下
  • 阴道
  • 其他的

第 8 章：经黏膜给药系统市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 医疗保健设施
  • 居家照护环境
  • 其他的

第九章：经黏膜给药系统市场－收入分析，2021-2031－地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 12 章：经黏膜给药系统市场 - 关键公司简介

  • Teva Pharmaceutical Industries Ltd
  • Cigna Corporation
  • BioDelivery Sciences International, Inc
  • 3M
  • Henkel Finland Oy
  • GlaxoSmithKline plc
  • Aquestive Therapeutics, Inc
  • Camurus AB
  • Ximedica
  • Noven Pharmaceuticals, Inc

第 13 章：附录

简介目录
Product Code: TIPRE00004209

The transmucosal drug delivery systems market is projected to increase from US$ 82.02 billion in 2024 to US$ 129.46 billion by 2031, with an estimated CAGR of 6.2% during the period from 2025 to 2031.

Analyst Perspective

Transmucosal drug delivery utilizes mucosal membranes, including oral, nasal, rectal, vaginal, ocular, and pulmonary mucosa, for administering drugs. This method offers significant advantages over traditional drug delivery routes, such as enhanced bioavailability, quick onset of action, avoidance of first-pass metabolism, and ease of administration. The report highlights growth opportunities based on current trends in the transmucosal drug delivery systems market and their anticipated effects throughout the forecast period.

Factors Propelling Growth in Transmucosal Drug Delivery Systems

Transmucosal drug delivery is favored for its sustained effectiveness. Noninvasive methods like intranasal, buccal, sublingual, and rectal routes allow for systemic drug delivery without the need for specialized personnel, making them particularly beneficial for caregivers and patients. Additionally, the rapid onset of action and reduced first-pass metabolism make these methods ideal for palliative and end-of-life care, providing quick symptom relief. Consequently, transmucosal delivery systems are increasingly utilized in managing chronic conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases. A study published by PubMed Central in January 2020 examined the safety and pharmacokinetics of dihydroergotamine (DHE) administered as intranasal DHE powder (STS101), intranasal DHE spray (Migranal), and intramuscular (IM) DHE injection in healthy subjects. The findings indicated that STS101 is a user-friendly, non-injected acute treatment for migraines with a favorable tolerability profile, expected to provide rapid and consistent pain relief while suppressing migraine symptoms without recurrence.

Many pharmacological agents are available in oral transmucosal forms, including cardiovascular drugs, sedatives, and analgesics. Biodegradable oral films facilitate drug delivery into systemic circulation, which is particularly advantageous for patients with dysphagia, frequent vomiting, hypertension, heart attacks, asthma, nausea, paralysis, and mental health disorders. These fast-dissolving oral films are thin adhesive strips placed on the tongue or other oral mucosal tissues.

Thus, the benefits of easy administration, high bioavailability, systemic drug availability, and rapid action are driving the growth of the transmucosal drug delivery systems market.

Strategic Insights

Report Segmentation and Scope

The "Global Transmucosal Drug Delivery Systems Market Analysis to 2031" is a comprehensive study of the pharmaceutical sector, focusing on global market trend analysis. The report aims to provide an overview of the market with detailed segmentation based on systems, end users, and geography. It includes key statistics on leading market players and highlights significant trends and opportunities in the market. The scope of the global transmucosal drug delivery systems market report covers North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Insights Based on Systems

The market is categorized into nasopulmonary, buccal & sublingual, vaginal, and other systems. The nasopulmonary segment accounted for the largest share of the transmucosal drug delivery systems market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

Insights Based on End Users

The market is divided into healthcare facilities, homecare settings, and others based on end users. The healthcare facilities segment held the largest market share in 2023, attributed to the availability of superior facilities and skilled healthcare professionals in hospitals. Furthermore, the homecare settings segment is projected to experience the highest CAGR from 2023 to 2031.

Regional Analysis

Geographically, the market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America held the largest share of the transmucosal drug delivery systems market in 2023, with the US leading this region. This dominance is due to the rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, along with an increasing number of product launches by key industry players.

Scope of the Transmucosal Drug Delivery Systems Market Report

Industry Developments and Future Opportunities:The forecast for the transmucosal drug delivery systems market can assist stakeholders in planning their growth strategies. According to company press releases, several strategic developments by leading players in the global market are outlined below:

In February 2024, Aquestive Therapeutics, Inc. showcased a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, presenting positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies on sublingual Anaphylm (epinephrine) film.

In August 2022, iX Biopharma Ltd launched IXB-322, a new initiative to expand its pipeline, focusing on developing a sublingual dexmedetomidine wafer for treating agitation in dementia and other conditions. This effort is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.

In May 2021, Tillotts Pharma AG, part of the Japanese Zeria Group, introduced a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine), a high-strength suppository for treating mild to moderate ulcerative proctitis symptoms in adults. This launch aims to provide innovative therapies for patients with gastrointestinal diseases, offering a convenient treatment option requiring only a single daily dose.

In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of its generic version of Casana 1 (mesalamine) suppository medicine, indicated for treating active ulcerative proctitis (ulcerative rectal colitis) in the US.

Key companies profiled in the transmucosal drug delivery systems market report include Teva Pharmaceutical Industries Ltd, Cigna Corporation, BioDelivery Sciences International, Inc, 3M, Henkel Finland Oy, GlaxoSmithKline plc, Aquestive Therapeutics, Inc, Camurus AB, Ximedica, and Noven Pharmaceuticals, Inc. These leading players are focused on expanding and diversifying their market presence and clientele, seizing business opportunities in the market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Transmucosal Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Transmucosal Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Transmucosal Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Transmucosal Drug Delivery Systems - Global Market Overview
  • 6.2 Transmucosal Drug Delivery Systems - Global Market and Forecast to 2031

7. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By System, 2021-2031

  • 7.1 Overview
  • 7.2 Nasopulmonary
  • 7.3 Buccal and Sublingual
  • 7.4 Vaginal
  • 7.5 Others

8. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 8.1 Overview
  • 8.2 Healthcare Facilities
  • 8.3 Homecare settings
  • 8.4 Others

9. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Transmucosal Drug Delivery Systems Market Overview
    • 9.1.2 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 9.1.3 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By System
    • 9.1.4 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Transmucosal Drug Delivery Systems Market
        • 9.1.5.1.1 United States Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.1.2 United States Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.2 Canada Transmucosal Drug Delivery Systems Market
        • 9.1.5.2.1 Canada Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.2.2 Canada Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.3 Mexico Transmucosal Drug Delivery Systems Market
        • 9.1.5.3.1 Mexico Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.3.2 Mexico Transmucosal Drug Delivery Systems Market, by End User
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Transmucosal Drug Delivery Systems Market - Key Company Profiles

  • 12.1 Teva Pharmaceutical Industries Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Cigna Corporation
  • 12.3 BioDelivery Sciences International, Inc
  • 12.4 3M
  • 12.5 Henkel Finland Oy
  • 12.6 GlaxoSmithKline plc
  • 12.7 Aquestive Therapeutics, Inc
  • 12.8 Camurus AB
  • 12.9 Ximedica
  • 12.10 Noven Pharmaceuticals, Inc

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud